Skip to main content
. Author manuscript; available in PMC: 2011 Dec 1.
Published in final edited form as: Pharm Res. 2010 Sep 25;27(12):2753–2765. doi: 10.1007/s11095-010-0277-5

Fig. 6.

Fig. 6

The effect of ADV (3.5 MHz, 3.7 μs pulse duration, 10 ms PRP, 4.7 MPa peak rarefactional pressure, 11.3 MPa peak compressional pressure, 5 minute exposure) on the ACT for five different thrombin formulations. Cases where the ACT was statistically different after ADV are denoted by an asterisk (*).